-Duncan J Stewart Researcher Activity Profile

Research Author Detailed Information 

Duncan J Stewart Publication Rate By Year

Duncan J Stewart has published 1 paper(s) in 1991, 1 paper(s) in 1994, 1 paper(s) in 2001, 1 paper(s) in 2003, 1 paper(s) in 2005, 5 paper(s) in 2006, 15 paper(s) in 2007, 6 paper(s) in 2008, for a total of 31 research publications in total.

Duncan J Dj Stewart Author Information

LAST NAME: stewart

FIRST NAME: Duncan J

INITIALS: dj

AFFILIATION:

Papers

Duncan J Stewart's Publication Record

1. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Year Published: 2006
Terrence Donnelly Heart Center, Division of Cardiology, St. Michael's Hospital, Toronto, Canada.
2. Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation? Year Published: 2006
Terrence Donnelly Heart Center, Vascular Biology Research Laboratory, Canada.
3. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Year Published: 2007
Department of Pediatrics, Division of Pediatric Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
4. Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysis. Year Published: 2007
Department of Epidemiology, Unit 1340, The University of Texas M. D. Anderson Cancer Center, 1155 Pressler Boulevard, Houston, TX 77030, USA.
5. Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle. Year Published: 2007
Division of Cardiology, Keenan Research Centre in the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada. leong-poih@smh.toronto.on.ca.
6. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. Year Published: 2007
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
7. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. Year Published: 2007
The Terrence Donnelly Research Laboratories, Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
8. ATM sequence variants associate with susceptibility to non-small cell lung cancer. Year Published: 2007
Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
9. Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Year Published: 2007
Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
10. Increased caveolin-1 expression precedes decreased expression of occludin and claudin-5 during blood-brain barrier breakdown. Year Published: 2007
Toronto Western Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada.
11. Endothelial progenitor cell therapy for the treatment of coronary disease, acute MI, and pulmonary arterial hypertension: Current perspectives. Year Published: 2007
Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada.
12. Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Year Published: 2007
Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
13. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. Year Published: 2007
The Terrence Donnelly Research Laboratories, Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
14. Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation? Year Published: 2006
Terrence Donnelly Heart Center, Vascular Biology Research Laboratory, Canada.
15. Increased caveolin-1 expression precedes decreased expression of occludin and claudin-5 during blood-brain barrier breakdown. Year Published: 2007
Toronto Western Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. su.nag@utoronto.ca
16. Endothelial progenitor cell therapy for the treatment of coronary disease, acute MI, and pulmonary arterial hypertension: current perspectives. Year Published: 2007
Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada.
17. Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation? Year Published: 2006
Terrence Donnelly Heart Center, Vascular Biology Research Laboratory, Canada.
18. Region-specific patterns of vascular remodelling occur early in atherosclerosis and without loss of smooth muscle cell markers. Year Published: 2008
Department of Laboratory Medicine & Pathobiology, University of Toronto, Canada.
19. Endothelial progenitor cell therapy for the treatment of coronary disease, acute MI, and pulmonary arterial hypertension: current perspectives. Year Published: 2007
Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada.
20. MR imaging of linitis plastica of the rectum. Year Published: 2003
Department of Radiology, Royal Preston Hospital, Sharoe Green Ln., Preston, PR2 9HT, United Kingdom.
21. Increased caveolin-1 expression precedes decreased expression of occludin and claudin-5 during blood-brain barrier breakdown. Year Published: 2007
Toronto Western Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. su.nag@utoronto.ca
22. Region-specific patterns of vascular remodelling occur early in atherosclerosis and without loss of smooth muscle cell markers. Year Published: 2008
Department of Laboratory Medicine & Pathobiology, University of Toronto, Canada.
23. Concomitant treatment with oral L-arginine improves the efficacy of surgical angiogenesis in patients with severe diffuse coronary artery disease: The Endothelial Modulation in Angiogenic Therapy randomized controlled trial. Year Published: 2008
Division of Cardiac Surgery, University of Ottawa, Ottawa, Ontario, Canada; Department of Epidemiology, University of Ottawa, Ottawa, Ontario, Canada.
24. Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer. Year Published: 2008
25. Concomitant treatment with oral L-arginine improves the efficacy of surgical angiogenesis in patients with severe diffuse coronary artery disease: the Endothelial Modulation in Angiogenic Therapy randomized controlled trial. Year Published: 2008
Division of Cardiac Surgery, University of Ottawa, Ottawa, Ontario, Canada. mruel@ottawaheart.ca
26. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. Year Published: 2008
Department of Diagnostic Imaging, University of Texas, M. D. Anderson Cancer Center, Sheba Medical Center, Tel Hashomer, Israel. emarom@di.mdacc.tmc.edu
27. Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding? Year Published: 2001
Department of Medicine, University of British Columbia and Vancouver General Hospital, Vancouver, Canada. mancini@interchange.ubc.ca
28. Endothelin-1--marker or mediator of vascular disease? Year Published: 1991
Division of Cardiology, Royal Victoria Hospital, Montreal, Quebec.
29. Acetylcholine stimulates release of endothelium-derived relaxing factor in coronary arteries of human organ donors. Year Published: 1994
30. Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension. Year Published: 2005
McGill University, Montreal, Quebec, Canada. david.langleben@mcgill.ca
31. Endothelial progenitor cell-coated stents under scrutiny. Year Published: 2006